a. Participant enrolment and inclusion in the final analysis. In total 446 participants (220 HIV positive and 226 HIV negative) were assessed for CH. b. Study analysis design. Genomic analysis for CH was performed blinded to the HIV status of the participant. Unblinding of HIV status and statistical analysis was performed once genomic analysis by targeted deep sequencing was complete.